DIEPENBEEK, Belgium, February 25, 2016 /PRNewswire/ --
- First contracts have been signed for a total of 200 000 patches.
- Negotiations with over 25 countries in EMEA, Asia and US.
After a successful launch at the Medica fair in Düsseldorf 3 months ago of the Bedalpatch, over 160 000 pieces have been sold to the company's homebase, the Benelux. Other contracts have been signed for Australia, Italy and Saudi-Arabia. On top of this positive start there are well-advanced negotiations with dealers in over 25 countries[1]. This exceeds the expectations of Bedal and has drawn the attention of the Belgian Minister of Welfare and Health, Jo Van Deurzen. He was so impressed by both the product as well as the company, that after his visit to the booth at Medica, Bedal has been referred to as an example for innovative entrepreneurship within the healthcare sector in his official communication (cfr press release). The participation at Medica and the launch of Bedalpatch happened with the support of Flanders Investment & Trade.
(Logo: http://photos.prnewswire.com/prnh/20150501/743212 )
(Photo: http://photos.prnewswire.com/prnh/20160225/337397 )
At this moment Bedal is in the process of obtaining the FDA label. The company expects to round up the process before summer. Together with the worldwide patent and the FDA label, Bedal is ready to sell the patch in the US and Canada, their biggest market.
No Longer A Single Product Company
There is a second product in the making derived from the same technology with the support of RMS, the Benelux dealer, and the Flemish government.
About Bedal
BEDAL NV is a medical technology company founded in 2011, dedicated to the development and commercialization of medical devices that increase patient comfort and hospital costs. The founders are three Belgian entrepreneurs from different sectors.
About the patch
Intravenous therapy is amongst the most widespread medical treatments. More than 60% of all patients in hospital receive intravenous therapy. One of the common downsides of this therapy is the effect on patient comfort: in order to wash or shower, an adequate shielding of the intravenous exit site is mandatory. Due to the lack of adequate solutions, most hospitals do not allow patients to wash while connected to an intravenous catheter. When showering is allowed, the time spent by hospital staff in assisting patients to shower represents significant costs.
Bedal develops solutions to allow patients to shower autonomously with a connected intravenous catheter, thus increasing patient comfort and reducing the time and material cost of hospitals.
Bedal is a partner of Flanders Care, an organisation of the Flemish government supporting innovation in healthcare.
More information: http://www.bedal.be
--------------------------------------------------
1. A.o: Japan, UK, Austria, India, Pakistan, United Arab Emirates, Iraq, Iran, Qatar, Egypt, Jordan, Lebanon, Kuwait, US, Canada, South Africa, Bahrain, Turkey. Furthermore interest has been shown from Israel, Panama, Peru, Colombia, Mexico, Norway and China.
Mail: [email protected]
Tel: +32-(0)11/28-69-02
SOURCE BEDAL NV
Share this article